Harrow's Q1 revenue and adjusted EBITDA missed expectations, exposing the need for improved revenue conversion and operating ...

If you are wondering whether Harrow's current share price lines up with its underlying worth, this breakdown will help you frame that question clearly before you decide what to do next. The stock ...

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the first quarter ended March 31, ...